NasdaqGS:EIDX

Stock Analysis Report

Executive Summary

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR).

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • Eidos Therapeutics has significant price volatility in the past 3 months.

Share Price & News

How has Eidos Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.1%

NasdaqGS:EIDX

-0.5%

US Biotechs

-0.02%

US Market


1 Year Return

340.7%

NasdaqGS:EIDX

-11.3%

US Biotechs

1.6%

US Market

EIDX outperformed the Biotechs industry which returned -10.2% over the past year.

EIDX outperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

EIDXIndustryMarket
7 Day7.1%-0.5%-0.02%
30 Day8.4%-2.1%2.7%
90 Day81.4%-1.9%1.4%
1 Year340.7%340.7%-10.6%-11.3%3.8%1.6%
3 Yearn/a4.6%1.1%45.2%35.8%
5 Yearn/a1.9%-3.0%61.8%44.1%

Price Volatility Vs. Market

How volatile is Eidos Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Eidos Therapeutics undervalued based on future cash flows and its price relative to the stock market?

32%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Eidos Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).

Eidos Therapeutics's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Eidos Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

Eidos Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Eidos Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Eidos Therapeutics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Eidos Therapeutics expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

-19.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Eidos Therapeutics is high growth as no revenue estimate data is available.

Eidos Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Eidos Therapeutics's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare Eidos Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Eidos Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Eidos Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Eidos Therapeutics performed over the past 5 years?

-69.9%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Eidos Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Eidos Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Eidos Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Eidos Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Eidos Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Eidos Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Eidos Therapeutics's financial position?


Financial Position Analysis

Eidos Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Eidos Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Eidos Therapeutics has no debt.

Eidos Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Eidos Therapeutics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Eidos Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.

Eidos Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 75% each year.


Next Steps

Dividend

What is Eidos Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Eidos Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Eidos Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Eidos Therapeutics has not reported any payouts.

Unable to verify if Eidos Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Eidos Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Eidos Therapeutics's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Neil Kumar (40yo)

3.5yrs

Tenure

US$823,148

Compensation

Dr. Neil Kumar, Ph.D., is a co-founder and has served as BridgeBio Pharma, Inc.'s Chief Executive Officer and a member of board of directors since April 2015. He serves as the Chief Executive Officer  ...


CEO Compensation Analysis

Neil's remuneration is lower than average for companies of similar size in United States of America.

Neil's compensation has increased whilst company is loss making.


Management Age and Tenure

2.3yrs

Average Tenure

50yo

Average Age

The tenure for the Eidos Therapeutics management team is about average.


Board Age and Tenure

1.5yrs

Average Tenure

48yo

Average Age

The average tenure for the Eidos Therapeutics board of directors is less than 3 years, this suggests a new board.


Insider Trading

Eidos Therapeutics individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$207,92306 Sep 19
Cameron Turtle
EntityIndividual
Role
Senior Key Executive
Chief Business Officer
Shares5,000
Max PriceUS$42.09
SellUS$180,62729 Jul 19
Uma Sinha
EntityIndividual
Role
Chief Scientific Officer
Chief Scientific Officer
Shares5,000
Max PriceUS$38.35
SellUS$600,56117 Jul 19
Jonathan Fox
EntityIndividual
Role
President
President & Chief Medical Officer
Shares15,000
Max PriceUS$40.04
BuyUS$26,382,79609 Jul 19
BridgeBio Pharma, Inc.
EntityCompany
Shares882,353
Max PriceUS$29.90
SellUS$509,48707 Jun 19
Christine Siu
EntityIndividual
Role
Chief Financial Officer
Chief Financial Officer
Shares17,000
Max PriceUS$31.03
SellUS$316,40206 Jun 19
Cameron Turtle
EntityIndividual
Role
Senior Key Executive
Chief Business Officer
Shares10,000
Max PriceUS$32.27
SellUS$163,17931 May 19
Jonathan Fox
EntityIndividual
Role
President
President & Chief Medical Officer
Shares5,000
Max PriceUS$32.64
BuyUS$28,622,77929 May 19
BridgeBio Pharma, Inc.
EntityCompany
Shares1,103,848
Max PriceUS$25.93
SellUS$136,37628 May 19
Uma Sinha
EntityIndividual
Role
Chief Scientific Officer
Chief Scientific Officer
Shares5,000
Max PriceUS$27.88
SellUS$125,15007 May 19
Jonathan Fox
EntityIndividual
Role
President
President & Chief Medical Officer
Shares5,000
Max PriceUS$25.03
SellUS$127,28704 May 19
Jonathan Fox
EntityIndividual
Role
President
President & Chief Medical Officer
Shares5,000
Max PriceUS$26.01
SellUS$115,55017 Apr 19
Jonathan Fox
EntityIndividual
Role
President
President & Chief Medical Officer
Shares5,000
Max PriceUS$23.11
BuyUS$542,06313 Dec 18
BridgeBio Pharma, Inc.
EntityCompany
Shares40,653
Max PriceUS$13.96
BuyUS$1,095,86713 Dec 18
BridgeBio Pharma, Inc.
EntityCompany
Shares80,144
Max PriceUS$14.36
BuyUS$15,464,91007 Dec 18
BridgeBio Pharma, Inc.
EntityCompany
Shares1,103,848
Max PriceUS$14.01
BuyUS$27,125,00007 Dec 18
BridgeBio Pharma, Inc.
EntityCompany
Shares1,750,000
Max PriceUS$15.50

Ownership Breakdown


Management Team

  • Christine Siu (42yo)

    Chief Financial Officer

    • Tenure: 1.8yrs
  • Hoyoung Huh (50yo)

    Consultant

    • Tenure: 0.8yrs
    • Compensation: US$724.60k
  • Uma Sinha (62yo)

    Chief Scientific Officer

    • Tenure: 3.3yrs
    • Compensation: US$5.48m
  • Neil Kumar (40yo)

    CEO & Director

    • Tenure: 3.5yrs
    • Compensation: US$823.15k
  • Jonathan Fox (62yo)

    President & Chief Medical Officer

    • Tenure: 2.9yrs
    • Compensation: US$1.71m
  • Isabella Graef (54yo)

    Founder & Board Advisor

    • Tenure: 0yrs
    • Compensation: US$150.00k
  • Cameron Turtle (29yo)

    Chief Business Officer

    • Tenure: 0.8yrs
    • Compensation: US$3.41m
  • Matt Outen

    Acting Chief Commercial Officer

    • Tenure: 0yrs

Board Members

  • Eric Aguiar (57yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: US$626.28k
  • Ali Satvat (42yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$610.45k
  • Raj Shah (42yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: US$622.32k
  • Bill Lis (55yo)

    Director

    • Tenure: 0.8yrs
    • Compensation: US$400.40k
  • Neil Kumar (40yo)

    CEO & Director

    • Tenure: 3.5yrs
    • Compensation: US$823.15k
  • Isabella Graef (54yo)

    Founder & Board Advisor

    • Tenure: 0yrs
    • Compensation: US$150.00k

Company Information

Eidos Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Eidos Therapeutics, Inc.
  • Ticker: EIDX
  • Exchange: NasdaqGS
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.826b
  • Shares outstanding: 37.44m
  • Website: https://www.eidostx.com

Number of Employees


Location

  • Eidos Therapeutics, Inc.
  • 101 Montgomery Street
  • Suite 2550
  • San Francisco
  • California
  • 94101
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EIDXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2018
6MXDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2018

Biography

Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-admini ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 01:12
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.